Pharmerging Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019-2026

Section 01 Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

Section 02 Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.3. Research Methodology

Section 03 Executive Summary
3.1. Global Pharmerging Market Snapshot

Section 04 Market Overview
4.1. Product Overview
4.2. Key Industry Developments

Section 05 Market Dynamics
5.1. Opportunity Analysis
5.2. Drivers and Restraints Snapshot Analysis
5.3. Drivers
5.3.1. Continuous Research and Development
5.3.2. Increasing Government Expenditure on Healthcare
5.3.3. Rising non-communicable diseases (NCDs)
5.3.4. Free trade agreement
5.3.5. Growing income
5.3.6. Aging population and increasing life expectancy
5.4. Restraints
5.4.1. Economic challenges in Africa
5.4.2. Weak or ambiguous patent laws
5.4.3. Growing medical tourism
5.4.4. Partnerships and acquisition of local players by MNCs
5.5. Porter’s Analysis
5.6. Value Chain Analysis (Medical Devices)
5.7. Value Chain Analysis (Pharmaceuticals)
5.8. Mergers and Acquisitions Landscape
5.9. Reimbursement Scenario
5.10. Pharmerging Market Outlook

Section 06 Global Pharmerging Market Analysis, by Product Type
6.1. Key Findings
6.2. Introduction
6.3. Market Forecast by Product Type
6.3.1. Pharmaceuticals
6.3.1.1. Branded Prescription Drugs
6.3.1.2. Generic Drugs
6.3.1.2.1. Branded Generic
6.3.1.2.2. Unbranded Generic
6.3.1.3. OTC Drugs
6.3.2. Healthcare
6.3.2.1. Medical Devices
6.3.2.2. In Vitro Diagnostic
6.3.2.3. Others (IT and record management)
6.4. Global Pharmerging Market Attractiveness Analysis, by Product Type
6.3. Key Trends

Section 07 Global Pharmerging Market Analysis, by Indications
7.1. Key Findings
7.2. Introduction
7.3. Market Forecast by Indications
7.3.1. Lifestyle Diseases
7.3.2. Cancers & Autoimmune diseases
7.3.3. Infectious diseases
7.3.4. Others
7.4. Global Pharmerging Market Attractiveness Analysis, by Indications

Section 08 Global Pharmerging Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Forecast by Distribution Channel
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Retail Pharmacies
8.3.4. E-commerce
8.3.5. Drug Stores
8.4. Global Pharmerging Market Attractiveness Analysis, by Distribution Channel
8.5. Key Trends

Section 09 Global Pharmerging Market Analysis, by Economic Growth Levels
9.1. Key Findings
9.2. Introduction
9.3. Market Forecast by Economic Growth Levels
9.3.1. Tier-1
9.3.2. Tier-2
9.3.3. Tier-3
9.4. Global Pharmerging Market Attractiveness Analysis, by Economic Growth Levels

Section 10 Global Pharmerging Market Analysis, by Region
10.1. Global Market Scenario, by Country
10.2. Global Pharmerging Market Value Share Analysis and Market Attractiveness Analysis, by Region
10.2.1. Market Forecast by Region
10.2.2. Latin America
10.2.3. Asia Pacific
10.2.4. Europe
10.2.5. Middle East & Africa

Section 11 Latin America Pharmerging Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Latin America Pharmerging Market Value Share Analysis, by Country
11.4. Latin America Pharmerging Market Forecast, by Country
11.5. Latin America Pharmerging Market Value Share Analysis, by Product Type
11.6. Latin America Pharmerging Market Forecast, by Product Type
11.7. Latin America Pharmerging Market Value Share Analysis, by Indications
11.8. Latin America Pharmerging Market Forecast, by Indications
11.9. Latin America Pharmerging Market Value Share Analysis, by Distribution Channel
11.10. Latin America Pharmerging Market Forecast, by Distribution Channel
11.11. Latin America Pharmerging Market Attractiveness Analysis

Section 12 Asia Pacific Pharmerging Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Asia Pacific Pharmerging Market Value Share Analysis, by Country
12.4. Asia Pacific Pharmerging Market Forecast, by Country
12.5. Asia Pacific Pharmerging Market Value Share Analysis, by Product Type
12.6. Asia Pacific Pharmerging Market Forecast, by Product Type
12.7. Asia Pacific Pharmerging Market Value Share Analysis, by Indications
12.8. Asia Pacific Pharmerging Market Forecast, by Indications
12.9. Asia Pacific Pharmerging Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Pharmerging Market Forecast, by Distribution Channel
12.11. Asia Pacific Pharmerging Market Attractiveness Analysis

Section 13 Europe Pharmerging Market Analysis
13.1. Key Findings
13.2. Market Overview
13.3. Europe Pharmerging Market Value Share Analysis, by Country
13.4. Europe Pharmerging Market Forecast, by Country
13.5. Europe Pharmerging Market Value Share Analysis, by Product Type
13.6. Europe Pharmerging Market Forecast, by Product Type
13.7. Europe Pharmerging Market Value Share Analysis, by Indications
13.8. Europe Pharmerging Market Forecast, by Indications
13.9. Europe Pharmerging Market Value Share Analysis, by Distribution Channel
13.10. Europe Pharmerging Market Forecast, by Distribution Channel
13.11. Europe Pharmerging Market Attractiveness Analysis

Section 14 Middle East & Africa Pharmerging Market Analysis
14.1. Key Findings
14.2. Market Overview
14.3. Middle East & Africa Pharmerging Market Value Share Analysis, by Country
14.4. Middle East & Africa Pharmerging Market Forecast, by Country
14.5. Middle East & Africa Pharmerging Market Value Share Analysis, by Product Type
14.6. Middle East & Africa Pharmerging Market Forecast, by Product Type
14.7. Middle East & Africa Pharmerging Market Value Share Analysis, by Indications
14.8. Middle East & Africa Pharmerging Market Forecast, by Indications
14.9. Middle East & Africa Pharmerging Market Value Share Analysis, by Distribution Channel
14.10. Middle East & Africa Pharmerging Market Forecast, by Distribution Channel
14.11. Middle East & Africa Pharmerging Market Attractiveness Analysis

Section 15 Competition Landscape
15.1. Competition Matrix
15.2. Pharmerging Market Share Analysis by Company, 2018
15.3. Company Profiles
15.3.1 Abbott Laboratories
15.3.1.1 Financial Overview
15.3.1.2. Product Portfolio
15.3.1.3. Business Strategies
15.3.1.4. Recent Developments
15.3.2 Koninklijke Philips N.V.
15.3.2.1 Financial Overview
15.3.2.2. Product Portfolio
15.3.2.3. Business Strategies
15.3.2.4. Recent Developments
15.3.3 F. Hoffmann-La Roche Ltd.
15.3.3.1 Financial Overview
15.3.3.2. Product Portfolio
15.3.3.3. Business Strategies
15.3.3.4. Recent Developments
15.3.4. Merck & Co., Inc.
15.3.4.1 Financial Overview
15.3.4.2. Product Portfolio
15.3.4.3. Business Strategies
15.3.4.4. Recent Developments
15.3.5 Novartis AG
15.3.5.1 Financial Overview
15.3.5.2. Product Portfolio
15.3.5.3. Business Strategies
15.3.5.4. Recent Developments
15.3.6 Johnson & Johnson
15.3.6.1 Financial Overview
15.3.6.2. Product Portfolio
15.3.6.3. Business Strategies
15.3.6.4. Recent Developments
15.3.7 Teva Pharmaceutical Industries Ltd.
15.3.7.1 Financial Overview
15.3.7.2. Product Portfolio
15.3.7.3. Business Strategies
15.3.7.4. Recent Developments
15.3.8. AstraZeneca
15.3.8.1 Financial Overview
15.3.8.2. Product Portfolio
15.3.8.3. Business Strategies
15.3.8.4. Recent Developments
15.3.9. GlaxoSmithKline plc.
15.3.9.1 Financial Overview
15.3.9.2. Product Portfolio
15.3.9.3. Business Strategies
15.3.9.4. Recent Developments
15.3.10. LUPIN
15.3.10.1 Financial Overview
15.3.10.2. Product Portfolio
15.3.10.3. Business Strategies
15.3.10.4. Recent Developments
15.3.11. Tata Consultancy Services Limited
15.3.11.1 Financial Overview
15.3.11.2. Product Portfolio
15.3.11.3. Business Strategies
15.3.11.4. Recent Developments
15.3.12. Sun Pharmaceutical Industries Ltd
15.3.12.1 Financial Overview
15.3.12.2. Product Portfolio
15.3.12.3. Business Strategies
15.3.12.4. Recent Developments
15.3.13. Huadong Medicine Co., Ltd
15.3.13.1 Financial Overview
15.3.13.2. Product Portfolio
15.3.13.3. Business Strategies
15.3.13.4. Recent Developments